Literature DB >> 2893841

Sedative action of the alpha 2-agonist medetomidine in cats.

D Stenberg1, P Salvén, M V Miettinen.   

Abstract

Medetomidine, a novel alpha 2-agonist drug intended for small animal sedation, was injected intramuscularly at dose rates of 0.02, 0.06 and 0.18 mg/kg. Xylazine (3.0 mg/kg) and saline were used for comparison. The five treatments were tested in a Latin square design in five cats. Treatments differed significantly in three-way analysis of variance, medetomidine inducing an increase in drowsiness with a corresponding decrease in both aroused waking and sleep determined by polygraphical criteria. The duration of effect was dose-dependent. The effect of 0.18 mg/kg medetomidine was comparable to 3.0 mg/kg of xylazine. The drugs also induced bradycardia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2893841     DOI: 10.1111/j.1365-2885.1987.tb00108.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  4 in total

1.  Evaluation of the muscular relaxant effect of dexmedetomidine or medetomidine in cats.

Authors:  P Scrollavezza; A M Tambella; C Vullo; A Palumbo Piccionello
Journal:  Vet Res Commun       Date:  2009-09       Impact factor: 2.459

2.  Immobilization of Norwegian reindeer (Rangifer tarandus tarandus) and Svalbard Reindeer (R. t. platyrhynchus) with medetomidine and medetomidine-ketamine and reversal of immobilization with atipamezole.

Authors:  N J Tyler; R Hotvedt; A S Blix; D R Sørensen
Journal:  Acta Vet Scand       Date:  1990       Impact factor: 1.695

3.  Clinical evaluation of medetomidine, a novel sedative and analgesic drug for dogs and cats.

Authors:  T Vähä-Vahe
Journal:  Acta Vet Scand       Date:  1989       Impact factor: 1.695

4.  Olfactory Information Storage Engages Subcortical and Cortical Brain Regions That Support Valence Determination.

Authors:  Christina Strauch; Thu-Huong Hoang; Frank Angenstein; Denise Manahan-Vaughan
Journal:  Cereb Cortex       Date:  2022-02-08       Impact factor: 5.357

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.